Literature DB >> 16816551

Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides.

Patricia S Fletcher1, Julie Elliott, Jean-Charles Grivel, Leonid Margolis, Peter Anton, Ian McGowan, Robin J Shattock.   

Abstract

OBJECTIVES: Establishment of an in vitro model to evaluate rectal safety and the efficacy of microbicide candidates.
DESIGN: An investigation and characterization of human colorectal explant culture for screening candidate microbicides to prevent rectal transmission of HIV-1 infection.
METHODS: Human colorectal explants were cultured at the liquid-air interface on gelfoam rafts. Phenotypic characterization of HIV-1 target cells was performed by fluorescence-activated cell sorter analysis. HIV-1 infection was determined by the measurement of p24 antigen release, viral RNA, and proviral DNA accumulation.
RESULTS: Colorectal explant CD4 T cells expressed higher CCR5 and CXCR4 levels compared with blood. Minor differences between the rectal and sigmoid colon were observed with a trend for slightly higher CCR5 and HLA-DR expression in cells from the sigmoid colon. Favourable culture conditions were established for colorectal tissue. Although tissue structure degenerated with time, CD4: CD8 cell ratios remained constant, and tissue supported productive HIV-1 infection. The ability of candidate microbicides to inhibit R5 HIV-1 infection was evaluated. Polyanion candidates, PRO2000 and dextrin sulphate, provided 99% protection at 1 microg/ml and 1 mg/ml, respectively, equivalent to 1/5000 and 1/40 of the vaginal formulations. The nucleotide reverse transcriptase inhibitor (NRTI) 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) provided protection at concentrations 1000-fold lower (10 microg/ml) than the proposed vaginal formulation (1%). Furthermore, non-NRTI UC-781 and TMC-120 provided greater than 99% inhibition at 3.3 or 0.33 microg/ml, respectively. No products demonstrated toxicity to rectal mucosa at inhibitory concentrations.
CONCLUSION: Colorectal explant culture was shown to be a useful tool for the preclinical evaluation of potential microbicides. The data suggest that rectally applied microbicides might provide protection from HIV-1 transmission.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16816551     DOI: 10.1097/01.aids.0000232230.96134.80

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  74 in total

1.  Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.

Authors:  Martha Stefanidou; Carolina Herrera; Naomi Armanasco; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Short Communication: Limited Anti-HIV-1 Activity of Maraviroc in Mucosal Tissues.

Authors:  Patricia Fletcher; Carolina Herrera; Naomi Armanasco; Jeremy Nuttall; Robin J Shattock
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-29       Impact factor: 2.205

3.  Retrocyclin RC-101 blocks HIV-1 transmission across cervical mucosa in an organ culture.

Authors:  Phalguni Gupta; Deena Ratner; Ming Ding; Bruce Patterson; Lisa C Rohan; Todd A Reinhart; Velpandi Ayyavoo; Xioli Huang; Dorothy L Patton; Bharat Ramratnam; Alexander M Cole
Journal:  J Acquir Immune Defic Syndr       Date:  2012-08-15       Impact factor: 3.731

Review 4.  Current concepts of HIV transmission.

Authors:  Gavin Morrow; Laurence Vachot; Panagiotis Vagenas; Melissa Robbiani
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

Review 5.  Topical Microbicides in HIV Prevention: State of the Promise.

Authors:  Jared M Baeten; Craig W Hendrix; Sharon L Hillier
Journal:  Annu Rev Med       Date:  2019-10-15       Impact factor: 13.739

6.  Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection.

Authors:  Peng Xiao; Sanjeev Gumber; Mark A Marzinke; Abhijit A Date; Thuy Hoang; Justin Hanes; Laura M Ensign; Lin Wang; Lisa Rohan; Edward J Fuchs; Craig Hendrix; Francois Villinger
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

Review 7.  Rectal microbicide development.

Authors:  Ian McGowan
Journal:  Curr Opin HIV AIDS       Date:  2012-11       Impact factor: 4.283

8.  CCR5- and CXCR4-tropic subtype C human immunodeficiency virus type 1 isolates have a lower level of pathogenic fitness than other dominant group M subtypes: implications for the epidemic.

Authors:  Awet Abraha; Immaculate L Nankya; Richard Gibson; Korey Demers; Denis M Tebit; Elizabeth Johnston; David Katzenstein; Asna Siddiqui; Carolina Herrera; Lucia Fischetti; Robin J Shattock; Eric J Arts
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 9.  Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.

Authors:  Charlene S Dezzutti; Florian Hladik
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

10.  A new class of dual-targeted antivirals: monophosphorylated acyclovir prodrug derivatives suppress both human immunodeficiency virus type 1 and herpes simplex virus type 2.

Authors:  Christophe Vanpouille; Andrea Lisco; Marco Derudas; Elisa Saba; Jean-Charles Grivel; Beda Brichacek; Francesca Scrimieri; Raymond Schinazi; Dominique Schols; Christopher McGuigan; Jan Balzarini; Leonid Margolis
Journal:  J Infect Dis       Date:  2010-02-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.